on morphology, the Ig gene rearrangement assay can provide more accurate information regarding BM involvement in malignant lymphomas.

Dong Jin Park¹, Hyoun Chan Cho², Jung Hye Kwon³, Ji-Young Park²

¹Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Departments of ²Laboratory Medicine and ³Internal Medicine, Hallym University College of Medicine, Kangdong Sacred Heart Hospital, Seoul, Korea

Correspondence to: Ji-Young Park
Department of Laboratory Medicine, Hallym University College of Medicine, Kangdong Sacred Heart Hospital, 150, Seongan-ro, Gangdong-gu, Seoul 05355, Korea
E-mail: parkjy@hallym.or.kr

Received on May 31, 2016; Revised on Aug. 6, 2016; Accepted on Sep. 6, 2016

https://doi.org/10.5045/br.2017.52.2.141

Authors’ Disclosures of Potential Conflicts of Interest
No potential conflicts of interest relevant to this article were reported.

REFERENCES
1. Lossos IS. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol 2005;23:6351-7.
2. Kang YH, Park CJ, Seo EJ, et al. Polymerase chain reaction-based diagnosis of bone marrow involvement in 170 cases of non-Hodgkin lymphoma. Cancer 2002;94:3073-82.
3. Sandberg Y, van Gastel-Mol EJ, Verhaaf B, Lam KH, van Dongen JJ, Langerak AW. BIOMED-2 multiplex immunoglobulin/T-cell receptor polymerase chain reaction protocols can reliably replace Southern blot analysis in routine clonality diagnostics. J Mol Diagn 2005;7:495-503.
4. van Krieken JH, Langerak AW, Macintyre EA, et al. Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 2007;21:201-6.
5. Fey MF, Pilkington SP, Summers C, Wainscoat JS. Molecular diagnosis of haematological disorders using DNA from stored bone marrow slides. Br J Haematol 1987;67:489-92.
6. Odenthal M, Siebolts U, Ernstenus K, Disse D, Dienes HP, Wickenhauser C. Immunoglobulin heavy chain gene analysis in bone marrow biopsies and corresponding lymph node specimens: dependency on pre-treatment, histological subtype and extension of B-cell lymphoma. Int J Mol Med 2008;21:569-76.
7. Abbas F, Yazbek SN, Shammaa D, Hoteit R, Fermanian P, Mahfouz R. Invivoscribe BIOMED-2 primer mixes in B-cell immunoglobulin gene rearrangement studies: experience of a molecular diagnostics laboratory in a major tertiary care center. Genet Test Mol Biomarkers 2014;18:787-90.
8. Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol 2011;29:1844-54.
9. Brisco MJ, Latham S, Sutton R, et al. Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia. J Mol Diagn 2009;11:194-200.
10. Ghorbian S, Jahanzad I, Javadi GR, Sakhinia E. Evaluation of IGK and IGL molecular gene rearrangements according to the BIOMED-2 protocols for clinical diagnosis of Hodgkin lymphoma. Hematology 2016;21:133-7.
11. Shin S, Kim AH, Park J, et al. Analysis of immunoglobulin and T cell receptor gene rearrangement in the bone marrow of lymphoid neoplasia using BIOMED-2 multiplex polymerase chain reaction. Int J Med Sci 2013;10:1510-7.

The imbalance of procoagulant and anticoagulant factors in patients with chronic liver diseases in North India

TO THE EDITOR: Patients with chronic liver diseases (CLD) tend to experience severe hemostatic anomalies because of reduced levels of most of the coagulant proteins and anticoagulant factors such as protein C, protein S, and antithrombin. In contrast, it has been observed that levels of certain procoagulant factors such as factor VIII and von Willebrand factor (vWF) levels may be increased [1]. Various mechanisms such as increased levels of vWF antigen and reduced synthesis of ADAMTS 13 cleavage protease have been described to explain elevated factor VIII levels in these patients [2]. Additionally, the fact that factor VIII is an acute-phase reactant could elucidate partly these findings [3]. Not only increased procoagulant factor levels but a reduction in these factors may also lead to prothrombotic tendency in these patients. Concurrent reduction in protein C and factor VIII may also result in the procoagulant imbalance. It is important to distinguish the mechanism for increased factor VIII level in CLD patients since its sustained elevations may provoke the thrombosis. This study was aimed to compare the levels of factor VIII and protein C in CLD patients with a superimposed acute insult [acute-on-chronic liver failure (ACLF)] and in patients with compensated cirrhosis (CC), and to detect the correlations between the two factors and the disease activity using Model for End-Stage Liver Disease (MELD) scores in these respective groups. Furthermore, the ratio of factor VIII and protein C levels was evaluated as an indicator of the severity of liver disease in both groups.

This prospective study comprising 2 groups of patients with underlying CLD in a tertiary care center in North India was approved by the institutional Review board, with written informed consent obtained from all participants. Group 1 included 58 patients with ACLF (Asian Pacific Association for the Study of the Liver criteria [4]), and group 2 included 58 patients with biopsy-proven CC. The blood samples for coagulation study were collected from...
both groups using vacutainers containing buffered sodium citrate (0.109 M, 3.2%). The samples were processed within 30 minutes of collection. The citrated tubes were centrifuged at 3,000 g for 10 minutes to obtain plasma and analyzed for factor VIII and protein C on a fully automated coagulometer. The factor VIII and protein C values between the 2 groups were compared using the Mann-Whitney test and those of each group were analyzed the correlation with their MELD scores using Pearson’s correlation. 

Patient characteristics are summarized in Table 1. The mean age in group 1 was 44.46±11.3 years with 89.7% being men, while in group 2, the mean age was 50.32±10.45 years with 94.8% being men. The median [interquartile range (IQR)] factor VIII and protein C levels in group 1 were 232.55% (150.0–331.5%) and 10.5% (10.25–22.10%), respectively, with a mean MELD score of 26.06±8.19. In group 2, the median (IQR) factor VIII and protein C levels were 178.20% (105.6–261.45%) and 36.8% (25.3–45.07%), respectively, with a mean MELD score of 16.19±3.91. The differences in factor VIII (P=0.04) and protein C (P<0.001) levels between the 2 groups were statistically significant.

The factor VIII levels in group 2 showed significantly positive correlation with MELD score, while those in group 1 did not show the significant correlation with their MELD score. A weak and negative correlation of protein C with MELD scores was seen in both groups, but it did not reach statistical significance. In addition to the above parameters, the ratio of factor VIII to protein C levels was calculated as an index of the procoagulant tendency in both groups. A statistically significant difference in the ratios between the 2 groups (P<0.001) was observed. The factor VIII to protein C ratio in group 1 showed a weak positive correlation with the MELD scores that was statistically insignificant, while the ratio in group 2 showed a weak positive but significant (P<0.001) correlation with MELD scores (Table 2).

Patients with CLD do not experience only bleeding complications but also thrombotic events. The main procoagulant drivers in CLD include elevated factor VIII and vWF and reduced protein C levels. Factor VIII elevations can arise from increased vWF levels, decreased expression of low-density lipoprotein receptor, and an acute-phase response to inflammation [2]. Of the 2 study groups included in our study, the ACLF group had patients with increased levels of C-reactive protein (44.0±29.3 mg/L) and procalcitonin (mean >2.10 ng/mL). However, the CC group had patients with no elevations of C-reactive protein (3±0.5 mg/L) and procalcitonin (mean <0.05 ng/mL). The factor VIII levels in both groups were elevated, but the elevation was significantly higher in the ACLF group, which can be attributed to additional acute insults. High factor VIII levels are a major risk factor in venous thrombosis [5] and may lead to thrombosis in CLD, especially in ACLF. Treatment of the acute-phase response in these patients might reduce the thrombotic tendencies.

Protein C levels are known to decrease in CLD as the liver is the major site of protein C synthesis. Our study has shown a significantly decrease in protein C levels in patients with ACLF (compared with the patients with CC), which may lead to an exacerbation of thrombotic tendencies in these patients. A negative correlation of protein C with the MELD score was observed in both groups, although the values were not statistically significant (Table 2).

Based on the fact that factor VIII is one of the most important components of thrombin generation and protein C is one of its most important inhibitors [6], the ratio of

| Table 1. Demographic and clinical characteristics of patients. |
|---------------------------------------------------------------|
| **Group 1 (N=58)** | **Group 2 (N=58)** | **P** |
| ------------------ | ------------------ | ------ |
| Age (mean±SD) | 44.46±11.3 | 50.32±10.45 | |
| Gender, male (%) | 89.7 | 94.8 | |
| MELD score (mean±SD) | 26.06±8.19 | 16.19±3.91 | |
| F8, % (median with IQR) | 232.55 (150.0–331.5) | 178.20 (105.6–261.45) | 0.04 |
| PrC, % (median with IQR) | 10.5 (10.2–22.1) | 36.8 (25.3–45.07) | <0.001 |
| F8:PrC ratio | 22.1 | 4.8 | <0.001 |

Abbreviations: F8, factor VIII; IQR, interquartile range; PrC, protein C; MELD, model for end-stage liver disease.

| Table 2. Correlations coefficients with MELD score for each parameters. |
|---------------------------------------------------------------|
| **Group 1 (N=58)** | **P** | **Group 2 (N=58)** | **P** |
| Factor VIII | 0.15 | 0.9 | 0.37 | 0.004 |
| Protein C | -0.3 | 0.09 | -0.2 | 0.13 |
| Factor VIII : Protein C ratio | 0.12 | 0.51 | 0.5 | <0.001 |

Abbreviation: MELD, model for end-stage liver disease.
the 2 components was considered as an indicator of pro-thrombotic tendency. We found values in patients with CC similar to those of Tripodi et al. [7], but patients with ACLF had significantly higher ratios (Table 2). The ratio in the patients with OC had a direct and significant correlation with the MELD score compared to the ACLF group in which the coagulopathic defects were more serious. In patients with ACLF, other causes of hemostatic defects except for CLD, making more complex and heterogeneous coagulopathies, might interrupt correlation with MELD scores compared to those with CC [4, 8].

To conclude, the patients with ACLF have higher factor VIII and lower protein C than those with CC. The factor VIII levels and the ratio of factor VIII to protein C may be used as a predictable marker for the severity of liver disease in patients with CC.

Priyanka Saxena¹, Chhagan Bihari², Roshni Mirza³, Ajeet Singh Bhadoria⁴, Shiv K Sarin⁵

¹Department of Pathology, Maulana Azad Medical College; ²Department of Pathology, Institute of Liver and Biliary Sciences; Departments of ³Hematology, ⁴Clinical Epidemiology, and ⁵Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India

Correspondence to: Priyanka Saxena
Department of Pathology, Maulana Azad Medical College, 1349, D-1, Vasant Kunj, New Delhi, India
E-mail: docpriya06@rediffmail.com

Received on Aug. 2, 2016; Revised on Sep. 23, 2016; Accepted on Nov. 18, 2016
https://doi.org/10.5045/br.2017.52.2.143

Authors’ Disclosures of Potential Conflicts of Interest
No potential conflicts of interest relevant to this article were reported.

REFERENCES
1. Lisman T, Caldwell SH, Burroughs AK, et al. Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol 2010;53:362-71.
2. Hollestelle MJ, Geertzen HG, Straatsburg IH, van Gulik TM, van Mourik JA. Factor VIII expression in liver disease. Thromb Haemost 2004;91:267-75.
3. Noe DA, Murphy PA, Bell WR, Siegel JN. Acute-phase behavior of factor VIII procoagulant and other acute-phase reactants in rabbits. Am J Physiol 1989;257:R49-56.
4. Sarin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009;3:269-82.
5. Kamphuisen PW, Eikenboom JC, Bertina RM. Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 2001;21:731-8.
6. Dahlbäck B. Progress in the understanding of the protein C anticoagulant pathway. Int J Hematol 2004;79:109-16.
7. Tripodi A, Primignani M, Lemma L, et al. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology 2010;52:249-55.
8. Agarwal B, Wright G, Gatt A, et al. Evaluation of coagulation abnormalities in acute liver failure. J Hepatol 2012;57:780-6.

The first case of paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome treated with complement inhibitor eculizumab in Korea

TO THE EDITOR: Budd-Chiari syndrome (BCS) is a rare and potentially life-threatening disorder characterized by hepatic venous outflow obstruction [1]. BCS is associated with thrombogenic conditions such as myeloproliferative neoplasms or inherited deficiencies in protein C, protein S, and antithrombin in at least 75% of patients [2]. However, paroxysmal nocturnal hemoglobinuria (PNH) is another well-recognized cause of BCS [3]. PNH is an acquired disorder of hematopoietic stem cells, characterized by chronic intravascular hemolysis, thromboembolic episodes, and varying degrees of bone marrow failure caused by uncontrolled complement activation [4]. Patients with BCS, in whom no other etiological factor has been identified after a thorough clinical and laboratory investigation, are required to be tested by routine flow cytometry screening for PNH in Western countries [5].

Eculizumab, a humanized monoclonal antibody that blocks the activation of terminal complement C5 components, is currently used in the treatment of PNH. Treatment with eculizumab reduces transfusion requirements, ameliorates anemia, decreases the risk of thrombosis, and improves quality of life by resolving the constitutional symptoms associated with chronic intravascular hemolysis [6, 7]. Long-term treatment with eculizumab in patients with concomitant BCS and PNH has shown a favorable safety profile [8-10]. To the best of our knowledge, this is the first report of eculizumab treatment in a patient with BCS and PNH in Korea.

CASE
A 39-year-old man was admitted to our hospital with newly developed abdominal pain, fatigue, pancytopenia, abdominal distension, and jaundice. He had a history of liver cirrhosis secondary to BCS and undergone splenectomy and inferior vena cava (IVC) stent insertion 15 years ago. The laboratory results on admission were as follows: white blood cell count, 3.2×10⁹/L; hemoglobin, 5.3 g/dL; platelets, 4.1×10⁹/L; reticulocyte count, 10.3%; haptoglobin, < 100 mg/L (lower limit of reference range, 300 mg/L); lactate dehydrogenase (LDH), 5,005 IU/L (upper limit of reference range, 269 IU/L).